Endpoints at #ASCO24

An in-depth discussion featuring Endpoints News Reporter Lei Lei Wu, and the Director of the National Cancer Institute, W. Kimryn Rathmell — covering her priorities in her first six months on the job and the outlook ahead for cancer research.

Join an Endpoints News reporter and a panel of leading cancer researchers, industry insiders, and experts to recap the major news out of ASCO and look ahead to what it means for oncology pipelines over the next year. We’ll cover the biggest data readouts from the conference, predictions around major themes in oncology, and upcoming anticipated FDA decisions and trials.

A cancer diagnosis can be terrifying and the treatment journey - including getting access to recommended therapies - daunting. How can industry and healthcare providers collaborate to address and overcome hurdles patients and communities face? We’ll be discussing the factors contributing to cancer care access challenges, including social determinants of health and how collaboration within the care ecosystem can play a vital role in creating positive change, enhanced patient experiences and improved outcomes.

BTK inhibitors have revolutionized the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL). With approved next-generation BTKis, there are more treatment options than ever before. But as new data emerge, the medical community faces new questions about how to select the right therapy for the right patient. Hear from leading hematology/oncology experts as they discuss the BTKi treatment landscape and the considerations healthcare providers and patients should weigh when choosing treatment for CLL.

An in-depth discussion featuring the Founder and Editor of Endpoints News, John Carroll, and Senior Vice President and Head of Oncology, Global Clinical Development at Merck, Marjorie Green.